The estimated Net Worth of Adrian Rawcliffe is at least $3.69 Million dollars as of 16 January 2024. Mr. Rawcliffe owns over 39,384 units of Adaptimmune Therapeutics Plc stock worth over $48,436 and over the last 9 years he sold ADAP stock worth over $1,494,222. In addition, he makes $2,148,260 as Chief Executive Officer and Director at Adaptimmune Therapeutics Plc.
Adrian has made over 22 trades of the Adaptimmune Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 39,384 units of ADAP stock worth $27,569 on 16 January 2024.
The largest trade he's ever made was selling 600,000 units of Adaptimmune Therapeutics Plc stock on 20 March 2018 worth over $1,026,000. On average, Adrian trades about 18,989 units every 51 days since 2016. As of 16 January 2024 he still owns at least 44,848 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr. Rawcliffe stock trades at the bottom of the page.
Adrian Rawcliffe serves as Chief Executive Officer, Director of the Company. He leads our financial strategy, management and operations functions including compliance and risk management. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK's Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK's venture-capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.
As the Chief Executive Officer and Director of Adaptimmune Therapeutics Plc, the total compensation of Adrian Rawcliffe at Adaptimmune Therapeutics Plc is $2,148,260. There are 1 executives at Adaptimmune Therapeutics Plc getting paid more, with James Noble having the highest compensation of $2,821,740.
Adrian Rawcliffe is 48, he's been the Chief Executive Officer and Director of Adaptimmune Therapeutics Plc since 2019. There are 18 older and 1 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
Adrian's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: